Figure 3

The number of NPCs in the DG was higher in the galectin-1 null mutant mouse than in controls. (A-D') The increase in the number of FABP7+/BrdU+ cells in the galectin-1 null mutant mouse brain was significant. (A) Time-line for the BrdU infusion experiment. BrdU was infused every 3.3 hours for 10 hours, and the mice were sacrificed 3.4 hours after the last injection. (B, B') BrdU+ cells in the DG of a galectin-1-null mutant mouse (B') and control (heterozygous) mouse (B). n = 5 mice each. Dotted lines outline the SGZ. (C) The number of BrdU+ cells in the DG of the KO mice was greater than in their heterozygous littermates. P < 0.05; n = 5 mice each. (D) The number of FABP7+/BrdU+ cells was greater in the DG of galectin-1 null mutant mice than in that of controls. P < 0.05; n = 5 mice each. (D') Double-labeling for FABP7 (red) and BrdU (green). Arrowheads indicate double-labeled cells. (E) High-power image of FABP7+/BrdU+ double-labeled cells in the SGZ. (F) The number of BrdU+/type 1 cells was greater in the galectin-1-null mutant mouse DG than in that of controls. P < 0.05; n = 5 mice each. (G) Time-line for the long-term BrdU infusion experiment. BrdU was given for 7 days, and the mice were sacrificed 10 days after the last day of BrdU administration. (H, H') BrdU+ cells in the galectin-1 null mutant mouse DG (H') and control mouse DG (H). P < 0.05; n = 5 mice each. Dotted lines outline the SGZ. (I) The number of DCX+/BrdU+ cells was greater in the galectin-1-null mouse DG. P < 0.05; n = 5 mice each. (J) Quantitative comparison of FABP7+/BrdU+, DCX+/BrdU+, and NeuN+/BrdU+ cells in the DG of the KO and control mice. Significant increases were seen in the DCX+/BrdU+ and NeuN+/BrdU+ cells in the KO DG. (J') Arrowheads indicate DCX (red) and BrdU (green) double-positive cells, and the arrow indicates a BrdU single-positive cell. (Scale bars: B, B', H, H', 100 μm; D', E, J', 5 μm).